Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

BIONEER

Provides solutions for molecular diagnostics including nucleic acid extraction instruments, real-time PCR instruments... read more Featured Products: More products

Download Mobile App





Bioneer’s Combination Tests for SARS-CoV-2 and Influenza Receive CE-IVD Marking

By LabMedica International staff writers
Posted on 19 Nov 2020
Bioneer (Daejeon, Korea) has received CE-IVD marking for two combination tests for SARS-CoV-2 and influenza - the AccuPower RV1 Real-Time RT-PCR Kit and AccuPower RV1 Multiplex Kit. More...


The AccuPower RV1 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The 5-in-1 multiplex kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube. The user-convenient premix type kit enables pipetting free diagnosis since all the components for the assay are contained within a tube. It uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity, and the vacuum-dried premix allows for stable and reproducible results. The test kit is compatible with the ExiStation and ExiStation 48 systems.

The AccuPower RV1 Multiplex Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube and uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity. The test kit is compatible with various systems, including Exicycler 96 (BIONEER), CFX 96 (Bio-rad), ABI7500 Fast (Thermofisher), and Quantstudio 5 (Thermofisher).




Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.